Publications | Lund University Publications

1 – 6 of 6

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=author%3D%22Lidbrink%2C+E%22+or+(documentType+any+%22bookEditor+conferenceEditor%22+and+editor%3D%22Lidbrink%2C+E%22)&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2013
Mark Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
Linderholm, B. K. ; Lidbrink, E. ; Tallroth, E. ; Einbeigi, Z. ; Svensson, H. ; von Wachenfeldt, A. ; Norberg, B. ; Carlsson, L. ; Olsson, M. E. and Bergh, J. , et al. (2013) In Breast 22(6). p.1142-1147
- Contribution to journal › Article
2012
Mark Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
Hatschek, T. ; Carlsson, L. ; Einbeigi, Z. ; Lidbrink, E. ; Linderholm, B. ; Lindh, B. ; Loman, Niklas ^LU ; Malmberg, M. ; Rotstein, S. and Soderberg, M. , et al. (2012) In Breast Cancer Research and Treatment 131(3). p.939-947
- Contribution to journal › Article
2009
Mark First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer
Bergh, J. ; Jönsson, Per-Ebbe ^LU ; Lidbrink, E. ; Trudeau, M. ; Eiermann, W. ; Brattstrom, D. ; Lindemann, J. ; Wiklund, F. and Henriksson, R. (2009) 32nd Annual San Antonio Breast Cancer Symposium In Cancer Research 69(24). p.490-491
- Contribution to journal › Published meeting abstract
2008
Mark A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
Margolin, S ; Carlsson, L ; Hellström, M ; Karlsson, P ; Lidbrink, E ; Linderholm, B ; Lindman, H ; Malmström, Per ^LU ; Sköld Pettersson, D and Bergh, J (2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.116-117
- Contribution to journal › Published meeting abstract
2007
Mark Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Wilking, N. ; Lidbrink, E. ; Wiklund, T. ; Erikstein, B. ; Lindman, H. ; Malmström, Per ^LU ; Kellokumpu-Lehtinen, P. ; Bengtsson, N. -O. ; Soederlund, G. and Anker, G. , et al. (2007) In Annals of Oncology 18(4). p.694-700
- Contribution to journal › Article
2000
Mark Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
Bergh, J ; Wiklund, T ; Erikstein, B ; Lidbrink, E ; Lindman, H ; Malmström, Per ^LU ; Kellokumpu-Lehtinen, P ; Bengtsson, N O ; Söderlund, G and Anker, G , et al. (2000) In The Lancet 356(9239). p.1384-1391
- Contribution to journal › Article

your query:: Remove author: Lidbrink, E